Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
about
Erythropoiesis-stimulating agents for myelodysplastic syndromesErythropoietin or darbepoetin for patients with cancerErythropoiesis-stimulating agents for myelodysplastic syndromesErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataErythropoiesis-stimulating agents for anaemia in chronic heart failure patientsErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataErythropoietin or Darbepoetin for patients with cancerVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsClinical problem solving: utility of sonography in oncologic patientsBiomolecular markers of cancer-associated thromboembolismVenous thromboembolism in the cancer population: pathology, risk, and preventionErythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefitWhat is the Best Treatment for a Cancer Patient with Thrombosis?Supportive management of patients with brain tumors.Exploring the effect of erythropoietin on mortality using USRDS data.Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished dataDrug-induced hematologic syndromesThromboembolic and bleeding complications in acute leukemia.Venous thromboembolism in cancer patients.Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialErythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancerEffects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial.Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital.Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus StudyDoping in sport: effects, harm and misconceptions.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes.Epidemiology and pathophysiology of cancer-associated thrombosis.Canadian supportive care recommendations for the management of anemia in patients with cancer.The Use of Epoetin-α in Revision Knee Arthroplasty.High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastomaAge-related changes in peripheral blood counts in humansThe evolving role of biosimilars in haematology-oncology: a practical perspective.
P2860
Q24186244-E44EF69E-58B6-4B31-8F6F-46BF07F84E04Q24202335-183006F3-6DA6-4E3B-BFE9-99E205596096Q24202526-C28FA765-26AA-4E48-9339-14F00EC97DADQ24240202-17DCE52B-28B1-4BC0-AC86-A66864EA6A58Q24241045-403BB630-4C0B-452F-8D01-706F30402B80Q24242864-5324D216-82FE-4A1D-A5F3-53B8E9A8DFDEQ24245464-351F5FE4-AEE7-4CF2-99ED-C8A51A41DC79Q26741697-5319ED40-5EA7-40BB-8F6D-E7C7C0F52A00Q26827538-ECF07A31-B494-48F7-8DC3-2B4B5CBE8D52Q26865716-45BE2355-AAD0-46AE-A4C5-7BB2238B5513Q26996508-61879AF8-F85E-462C-8D82-3D4C13F717DBQ26999850-9FE00CFB-F741-48E6-83B0-01E29717CAF4Q27009514-5F5624C9-664E-4068-98A5-67366EBE6E11Q30444752-57C0CCF2-C8FD-4B55-97E8-0227A384466FQ30620811-1AE99D46-465F-4CF3-9210-2B5282598B84Q30803363-824A3D07-8BE8-475C-A303-E0FB37F351F4Q33387312-741E986E-7956-4A02-A673-BA430AB7110CQ33392897-F7FC2EC2-03DB-4E97-8245-5C7A0B8F818DQ33419213-1114DBB3-D4C0-4520-82F3-8EA12C61CA8BQ33499897-C71F0CF0-F15B-4319-802E-BAD26A3769A6Q33630871-5E9AC714-D0B1-45B2-BCCD-F7216CFE2173Q33659628-61FED1BC-73E2-4272-99C7-FD7D0E8A55E8Q33726150-828A7921-564F-4C08-8A82-4A83389A585AQ33893093-60593F9D-8817-4943-94CA-6B90A678EEF2Q33985838-926F9D34-1B8F-4839-AC82-D5C883C07954Q34022950-2A3FA3DA-96BD-4520-ACD0-1C6F7ECD9CADQ34403856-747945C6-235F-4D62-9022-149C1AEE3E45Q34446275-C933DDB4-178D-48CD-8B13-D3D957113BA6Q34635638-F639D909-8338-46B7-B653-4DC5F6E0B1CAQ35164312-CFE47EFA-AFA9-428C-8BD4-F7B26EFB0839Q35174604-F2AF9BA0-03DE-46CB-AF6E-CC3E4DD26CAEQ35217404-238A89CE-1185-45C9-A2A6-7AE1A518A860Q35620681-EFF4B476-2F61-4119-9BA7-A30A9FFD0EB5Q35642998-0861A270-45E0-41FF-962D-45B2D962F3B2Q35860789-BB8B860E-5ACE-468A-970C-5AB2D1F4A1A1Q36029750-ADAC07CD-DD39-479B-897D-DD88ED1C9B8DQ36091004-28154210-F5F7-4FA5-B8F8-B7862F49977FQ36230547-CF6F79DA-1341-4A81-82AE-310332290D09Q36246727-2DFAB444-0226-4E86-B211-F50228746064Q36291259-E1EDE858-FA16-4914-8D26-975253F9A069
P2860
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Recombinant human erythropoiet ...... udies including 9353 patients.
@ast
Recombinant human erythropoiet ...... udies including 9353 patients.
@en
type
label
Recombinant human erythropoiet ...... udies including 9353 patients.
@ast
Recombinant human erythropoiet ...... udies including 9353 patients.
@en
prefLabel
Recombinant human erythropoiet ...... udies including 9353 patients.
@ast
Recombinant human erythropoiet ...... udies including 9353 patients.
@en
P2093
P2860
P31
P50
P921
P356
P1476
Recombinant human erythropoiet ...... udies including 9353 patients.
@en
P2093
Andreas Engert
Charles L Bennett
Chris Hyde
Guido Schwarzer
Jayne Wilson
Jerome Seidenfeld
Josie Sandercock
Margaret Piper
Olaf Weingart
Simon Langensiepen
P2860
P304
P356
10.1093/JNCI/DJJ189
P407
P577
2006-05-01T00:00:00Z